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OBJECTIVES We determined the profile of cardiovascular risk factors in children late after Kawasaki disease
(KD) and compared it with that of age-matched healthy children.
BACKGROUND Concerns have been raised regarding the possibility of a predisposition of KD to premature
atherosclerosis later in life.
METHODS A cohort of 102 subjects were studied: 37 KD patients with coronary aneurysms (group I), 29
KD patients with normal coronary arteries (group II), and 36 healthy age-matched children
(group III). The fasting total cholesterol, high-density lipoprotein (HDL) cholesterol,
low-density lipoprotein (LDL) cholesterol, apolipoprotein (apo) A-I, apoB, and homocys-
teine levels were compared among the three groups. In addition, blood pressure and
brachioradial arterial stiffness, as determined by pulse wave velocity (PWV), were measured
and compared.
RESULTS Group I subjects had lower HDL cholesterol (p  0.016) and apoA-I levels (p  0.044) and
higher apoB levels (p  0.029) and PWV (p  0.001) than group III control subjects.
Likewise, the apoB levels (p  0.007) and PWV (p  0.042) were higher in group II than
in III subjects, although their HDL cholesterol (p  0.54) and apoA-I (p 0.52) levels were
similar. The LDL cholesterol levels were higher in group I and II patients than in controls,
although not statistically significant (p  0.17). Blood pressure and homocysteine levels did
not differ among the groups.
CONCLUSIONS An adverse cardiovascular risk profile, as characterized by a proatherogenic alteration of the
lipid profile and increased arterial stiffness, occurs in children after KD. The profile is worse
in those with than in those without coronary aneurysms. (J Am Coll Cardiol 2004;43:
120–4) © 2004 by the American College of Cardiology Foundation
It has now been more than 25 years since the first descrip-
tion of Kawasaki disease (KD) (1). Concerns have been
raised regarding the possibility of its predisposition to
premature atherosclerosis in adulthood (2–6). Nonetheless,
data on the cardiovascular risk profile long after resolution
of the acute phase of KD remain limited and, in some
aspects, controversial (6–9).
Alteration of the lipid profile during acute-phase KD,
with a decrease in total cholesterol, high-density lipoprotein
(HDL) cholesterol and apolipoprotein (apo) A-I levels, has
been well documented (8–10). Nonetheless, whether such
alterations persist after resolution of the acute inflammation
is controversial (8–10). Furthermore, data on low-density
lipoprotein (LDL) cholesterol and apo concentrations late
after the acute illness are not available.
A number of novel cardiovascular risk factors have re-
cently been described in adults. Arterial stiffness has recently
been shown to be an independent predictor of cardiovascu-
lar morbidity and mortality in adult patients with hyperten-
sion (11) and end-stage renal disease (12). Increased coro-
nary (13) and carotid (14) arterial stiffness has been
documented in KD patients with coronary aneurysms.
However, whether stiffness of peripheral conduit arteries is
likewise altered in those with and without aneurysms
remains unknown. More importantly, the interplay between
arterial stiffness and other cardiovascular risk factors has
hitherto not been explored. An elevated homocysteine level
has also been demonstrated to be an independent risk factor
for atherosclerosis in adults (15). Reduced methylenetetra-
hydrofolate reductase (MTHFR) activity, among other
determinants, is associated with a moderately elevated
homocysteine level (16). Although MTHFR gene polymor-
phism has been implicated in a predisposition to coronary
aneurysm formation in children with KD (17), the plasma
homocysteine levels in these patients are unknown.
In this study, we determined the profile of novel and
traditional cardiovascular risk factors in KD patients late
after resolution of the acute illness and compared the
findings with those of age-matched healthy children. We
further determined the inter-relationships between blood
pressure (BP), lipid and homocysteine levels, and peripheral
conduit arterial stiffness.
METHODS
Subjects. Patients with history of KD were recruited from
the pediatric cardiac clinic of Grantham Hospital. All of the
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recruited patients had a normal left ventricular shortening
fraction and absence of valvar incompetence, as documented
by serial echocardiographic studies. Patients diagnosed as
having KD within 12 months of the study were excluded to
minimize a potential confounding influence relating to
subacute inflammation (18). Healthy age-matched subjects
were recruited as control subjects. These were healthy
children previously discharged from our clinic with a diag-
nosis of a functional heart murmur and their healthy
siblings. The institutional ethics committee approved the
study, and the parents of all subjects gave written, informed
consent.
The subjects attended for the study after an overnight
fast. Body weight and height were measured, and body mass
index was calculated accordingly. All subjects rested for at
least 15 min before BP and vascular assessments. Blood
pressure in the right arm was measured twice using an
automatic oscillometric device (Dinamap, Critikon Inc.,
Tampa, Florida), with the subjects in the seated position,
and the average of the two readings was taken. Assessment
of peripheral conduit arterial stiffness and blood withdrawal
was then performed sequentially, as described subsequently.
From the medical records, the following patient data were
retrieved: interval from disease onset to time of study,
coronary complications, cardiac symptoms, and medications
at the time of study. Coronary aneurysms were documented
by serial two-dimensional echocardiography. Based on the
patients’ status and the presence or absence of coronary
complications, the cohort was categorized into three groups
for comparisons. Group I comprised patients with coronary
aneurysms, whether persistent or regressed; group II com-
prised patients without coronary complications; and group
III comprised healthy control subjects.
Measurement of arterial stiffness. Stiffness of the brachio-
radial arterial segment was assessed by measuring the pulse
wave velocity (PWV), with the subjects lying supine. Pulse
wave velocity is related to the square root of elastic modulus,
according to the Moens-Korteweg equation (19). Hence,
the stiffer the artery, the faster the PWV. A previously
validated photoplethysmographic technique (20) was used
to measure the transit time required for the pulse to travel
from the brachial artery at the elbow to the radial artery at
the wrist. The transit time was determined from the time
delay between the foot of the corresponding brachial and
radial pulse waves. The average of three readings was taken.
Pulse wave velocity was calculated by dividing the distance
between the two points by transit time. Intraobserver
variability for measurement of PWV, as determined from
the mean and SD of the differences in two consecutive
results from 20 studies, was 0.08  0.82 m/s.
Blood investigations. Venous blood was withdrawn for
measurement of fasting total cholesterol, triglycerides,
HDL cholesterol, LDL cholesterol, apoA-I, apoB, and
total plasma homocysteine levels. Plasma total cholesterol
level was determined enzymatically using a Hitachi 912
analyzer (Roche Diagnostics, GmbH, Mannheim, Ger-
many). The HDL cholesterol was measured using a homo-
geneous method with polyethylene glycol-modified en-
zymes and sulphated alpha-cyclodextrin. The LDL
cholesterol was calculated by the Friedewald equation.
Levels of apoA-I and apo B were determined by rate
nephelometric assays on the Image analyzer (Beckman
Coulter Inc., Fullerton, California). Total plasma homocys-
teine was measured by the AxSYM homocysteine assay
(Abbott Laboratories Inc., Abbott Park, Illinois), based on
the fluorescence polarization immunoassay technology.
Data analysis. Data are presented as the mean  SD,
unless otherwise stated. To compare differences in variables
among the three groups, one-way analysis of variance
(ANOVA) was performed. When values of p  0.05 were
yielded by ANOVA, multiple comparisons between two
groups by the unpaired Student t test were performed. All of
the p values are presented, and no correction was made for
the multiple tests. For categorical variables, the chi-square
test was performed. Pearson correlation analysis was used to
assess the correlation between brachioradial PWV and other
cardiovascular risk factors. Stepwise multiple linear regres-
sion was used to identify significant determinants of bra-
chioradial PWV. A value of p  0.05 was considered
statistically significant. All statistical analyses were per-
formed using SPSS version 10.0 (SPSS Inc., Chicago,
Illinois).
RESULTS
Subjects. A total of 102 subjects were studied. All of the
subjects were Chinese in origin. Group I comprised 37
patients, 21 of whom had persistent coronary aneurysms,
whereas 16 had aneurysms that had regressed. Group II
comprised 29 patients who did not have coronary compli-
cations. Of the total of 66 patients with KD, all but 5
patients had received intravenous immunoglobulin therapy
during the acute phase of the illness, and 32 patients were
maintained on long-term aspirin therapy. Group I patients
were studied at 7.8  3.7 years after KD, whereas group II
patients were studied at 6.2  2.4 years since the illness
(p  0.08). None were symptomatic and none required
coronary artery interventions. Group III comprised 36
healthy control subjects. The demographic and hemody-
namic data of the three groups are summarized in Table 1.
There were no significant differences in age, gender distri-
Abbreviations and Acronyms
ANOVA  analysis of variance
apo  apolipoprotein
BP  blood pressure
HDL  high-density lipoprotein
KD  Kawasaki disease
LDL  low-density lipoprotein
MTHFR  methylenetetrahydrofolate reductase
PWV  pulse wave velocity
121JACC Vol. 43, No. 1, 2004 Cheung et al.
January 7, 2004:120–4 Cardiovascular Risk Factors After KD
bution, body mass index, and systemic BP among the three
groups.
Lipid profile. The lipid profile of the cohort is summarized
in Table 2. The HDL cholesterol was significantly lower in
group I subjects (Fig. 1) than in both group II (p  0.046)
and III (p  0.016) subjects. This resulted in an increased
ratio of total cholesterol to HDL cholesterol in group I
subjects. The apoA-I level was likewise significantly lower
in group I subjects (Fig. 1). There was a strong correlation
between HDL cholesterol and apoA-I levels (r  0.73, p 
0.001).
The apoB levels, on the other hand, were significantly
higher in group I (p  0.029) and group II (p  0.007)
subjects than in controls. There was a similarly strong
correlation between LDL cholesterol and apoB levels (r 
0.63, p  0.001). However, although LDL cholesterol
levels appeared higher in group I and II subjects than in
controls (Table 2), the differences were not statistically
significant. No statistically significant differences in total
cholesterol (p  0.78) and triglyceride levels (p  0.07)
were found among the three groups.
Homocysteine level. The serum homocysteine levels in
group I, II, and III subjects were 6.16  2.41 mol/l, 5.63
 1.98 mol/l, and 5.76  1.64 mol/l, respectively. The
differences among the groups were not significant (p 
0.55).
Arterial stiffness. The PWV of group I subjects (7.17 
1.79 m/s) was significantly higher than that of control
subjects (5.89  1.35 m/s, p  0.001). Likewise, compared
with controls, the PWV of group II subjects was signifi-
cantly higher (6.71  1.82 m/s, p  0.042). There was,
however, no significant difference in PWV between group I
and group II subjects (p  0.32) (Fig. 2).
For the entire cohort, PWV correlated with age (r 
0.29, p  0.003), height (r  0.28, p  0.004), systolic BP
(r  0.29, p  0.003), diastolic BP (r  0.23, p  0.021),
homocysteine level (r  0.343, p  0.001), and LDL
cholesterol level (r  0.198, p  0.047). In patients, PWV
correlated with the duration since the onset of KD (r 
0.30, p  0.032).
Multiple linear regression analysis of the entire cohort
was used to identify significant determinants of PWV. The
dependent variables included age, gender, height, weight,
subject grouping, systolic and diastolic BPs, and homocys-
teine, HDL cholesterol, LDL cholesterol, apoA-I, apoB,
and triglyceride levels. Significant determinants were subject
grouping (beta  0.23, p  0.014), diastolic BP (beta 
0.22, p  0.018), homocysteine level (beta  0.29, p 
0.002), and LDL cholesterol level (beta  0.19, p  0.041,
model R2  0.26). When only the patient cohort (groups I
and II) was analyzed, with the addition of duration since the
onset of KD as a covariate into the multivariate model, only
LDL cholesterol level was found to be significant (beta 
0.83, p  0.011, model R2  0.26).
DISCUSSION
This study demonstrates that children with a history of KD
have an adverse cardiovascular risk profile long after reso-
lution of the acute inflammatory illness. In those with
coronary aneurysms, the profile is characterized by low
HDL cholesterol and apoA-I levels, high apoB levels, and
increased peripheral conduit arterial stiffness. In those
without coronary complications, apoB levels and brachio-
radial arterial stiffness are likewise increased. Although the
LDL cholesterol levels are higher in patients than in









Age (yrs) 9.0  3.1 8.9  3.2 9.1  2.6 0.96
Gender (M/F) 23/14 20/9 24/12 0.84
BMI (kg/m2) 16.9  2.7 16.0  2.7 16.9  3.4 0.37
SBP (mm Hg) 108  14 107  8 108  11 0.85
DBP (mm Hg) 58  9 58  5 57  8 0.95
Data are presented as the mean  SD.
ANOVA  analysis of variance; BMI  body mass index; DBP  diastolic blood pressure; SBP  systolic blood pressure.









p Value (Unpaired t Test)
I vs. III II vs. III I vs. II
Total cholesterol (mmol/l) 4.38  0.85 4.42  0.82 4.28  0.75 0.78
HDL cholesterol (mmol/l) 1.34  0.26 1.46  0.25 1.51  0.33 0.037* 0.016* 0.54 0.046*
Total cholesterol/HDL cholesterol ratio 3.37  0.80 3.08  0.57 2.92  0.61 0.016* 0.008* 0.29 0.095
ApoA-I (g/l) 1.22  0.21 1.34  0.19 1.32  0.17 0.026* 0.044* 0.52 0.018*
LDL cholesterol (mmol/l) 2.65  0.74 2.64  0.73 2.37  0.67 0.17
ApoB (g/l) 0.75  0.22 0.81  0.28 0.65  0.16 0.022* 0.029* 0.007* 0.18
Triglycerides (mmol/l) 0.86  0.34 0.70  0.27 0.88  0.37 0.07
*Statistically significant. Data are presented as the mean  SD.
ANOVA  analysis of variance; Apo  apolipoprotein; HDL  high-density lipoprotein; LDL  low-density lipoprotein.
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controls, the difference did not reach statistical significance.
In addition, we did not find any significant differences in
total plasma homocysteine levels and systemic BP between
patients and controls.
Lipid abnormalities in the acute phase of KD, with
decreased total cholesterol, HDL cholesterol, and apoA-I
levels, are reminiscent of those in acute infection and
inflammation (8–10,21). Although several studies have
suggested that such changes are transient (9,10), Newburger
et al. (8) have reported that HDL cholesterol levels remain
low as long as three years after the initial illness. The
findings of the present study, performed at a mean of 7.1
years after the initial illness, agree with those of Newburger
et al. (8) and further clarify that low HDL cholesterol levels
are confined to patients with coronary aneurysm formation.
As the severity of vasculitis in the acute phase is, to some
extent, reflected by development of coronary lesions (22),
our findings suggest that the degree of inflammation in the
acute phase may have important bearings on late lipid
abnormalities. Additionally, we have demonstrated low
apoA-I levels in patient subgroup, a consistent finding, as
apoA-I is the major protein constituent of plasma HDL.
This might have important implications, however, because
apoA-I, to a large extent, sets the plasma HDL levels (23)
and is demonstrated to be antiatherogenic in transgenic
mouse models (24). Besides apoA-I abnormalities, we have
demonstrated significantly higher apoB levels in KD pa-
tients, more so in those with coronary aneurysms, a finding
that has not been reported before. The finding that LDL
levels do not differ significantly among the groups does not
abrogate the overall adverse lipid profile in the KD groups,
as apoB reflects the abundance of all the atherogenic
lipoprotein particles—namely, LDL, intermediate-density
lipoprotein, very-low-density lipoprotein, and lipopro-
tein(a). Indeed, apoB has been regarded as a better indicator
of the attendant risk of coronary artery disease than LDL
cholesterol in adults (25,26). To our knowledge, this is the
first study to assess apo levels long term after KD.
The changes in cholesterol and lipoprotein levels long
term after KD mimic those proposed to be atherogenic.
Nonetheless, the underlying mechanisms remain specula-
tive. Endothelial dysfunction has been shown years after
resolution of the acute illness (7). Diminished lipoprotein
lipase activity with reduced generation of HDL cholesterol,
as a result of endothelial dysfunction, has been proposed as
a possible mechanism (8). Furthermore, inhibition of li-
poprotein lipase may decrease apoA-I levels by increasing its
catabolism (27). The cause for the higher apoB and LDL
cholesterol levels is unknown. Nonetheless, increased LDL
cholesterol levels have been described in adults with chronic
inflammation due to rheumatoid arthritis (28). Indeed,
there is increasing evidence that low-grade vasculitis con-
tinues unabated after the end of the acute phase of KD (29).
The changes in the lipid profile in our cohort may hence be
a reflection of such a continued low-grade inflammatory
process.
In addition to demonstrating a proatherogenic lipid
profile, we have shown that KD patients, including those
without coronary complications, have an increased brachio-
radial PWV and hence peripheral conduit arterial stiffness.
This supplements the findings of those of Noto et al. (14),
who demonstrated increased carotid arterial stiffness, using
a stiffness index that relates systemic BP to a pulsatile
change in carotid artery diameter, only in patients with
coronary aneurysms. It is possible that diffuse vasculitis in
the acute phase and the subsequent reparative process may
lead to replacement of elastic tissue by fibrous scar (30),
resulting in changes in the arterial wall structure and hence
its elastic modulus. Endothelial dysfunction after KD (7) is
probably also contributory in light of the crucial role of the
endothelium in the regulation of vascular tone.
Pulse wave velocity is directly related to characteristic
Figure 1. Distribution of high-density lipoprotein (HDL) cholesterol
(solid lines) and apolipoprotein (apo) A-I (dashed lines) levels in the three
groups of subjects (*p  0.046 vs. group II and p  0.016 vs. group III;
**p 0.018 vs. group II and p 0.044 vs. group III). Error bars represent
the mean  SEM.
Figure 2. Scatter plots of pulse wave velocity in the three groups of
patients. Horizontal lines represent the means of the groups.
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impedance (19). Importantly, the ascending aortic input
impedance, which represents the hydraulic load presented
by the systemic circulation to the left ventricle, is the
composite of the impedance spectra of vascular beds per-
fused by the ascending aorta (19). Hence, an increase in
characteristic impedance in the peripheral conduit artery
may contribute to an increase in this hydraulic load. Fur-
thermore, the increase in arterial stiffness may contribute to
the pathogenesis of hypertension (31). In the present study,
however, we did not find any difference in systemic BP
between patients and controls. In contrast, Silva et al. (6)
reported a higher systolic and diastolic BP in patients
studied at 11 years after KD. Nonetheless, the oscillometric
BP readings in their subjects were converted to z scores
using normative data that were obtained by the auscultatory
method. Given that oscillometric readings were higher than
readings obtained by auscultation (32), their results should
be interpreted with caution.
Conclusions. An adverse cardiovascular profile, as charac-
terized by a proatherogenic alteration of the lipid profile and
increased arterial stiffness, occurs in patients after KD. The
profile is worse in patients with than in those without
coronary aneurysms. Regular monitoring of these cardiovas-
cular risk factors is hence warranted in the long-term
follow-up of these patients.
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